Description
This report takes a look at both prevention procedures such as sterilization and surface area disinfection and testing such as molecular tests and immunoassays. Infection control in healthcare facilities deals largely with protecting building occupants from patients with communicable infectious diseases. Infections, which may result from activities and procedures taking place within the facility, have become a cause for great concern. Infection that is acquired during the course of healthcare is known as a nosocomial, or hospital acquired, infection.
What is the size of the market for healthcare infections testing and prevention? What are the top companies in the market? What is the expected growth in the future? The scourge of healthcare-associated infections or hospital acquired infections, or HAIs, is a real concern for healthcare providers. They stand to lose profit and contribute to negative patient outcomes if they do not control these infections. This has created market for three types of products, products to prevent, products to test for disease and then treatment products. This report deals with the first two, and looks how the markets interplay.
In some European countries, including the United Kingdom, screening for aggressive infections such as MRSA is performed in many hospitals upon admission.
As part of its coverage, this report includes:
Markets for HAI Testing and HAI Prevention, 2016-2021
Description of Infections
Hospital Spending Priorities
Cost of HAIs
The Basics – About Nosocomial Infections (HAIs)
Prevention Segments for Disinfectants, Sterilization and Wide Area Disinfection
The Prevention Effect
Testing Segments – Immunoassays, Molecular, Microbiology
Important Conclusions about the Market
The infection may occur in a postoperative wound or as a complication unrelated to the disease or condition. The U.S. Centers for Disease Control and Prevention (CDC) estimates that around 1 in 20, or 5%, of hospitalized patients will contract an HAI. Worldwide, the rate of nosocomial infections is between 3.5% and 12% of admissions in developed regions.
The prevention market consists of technologies and consumables to reduce the risk of infection transmission. These include:
Heat/steam sterilization systems
Chemical sterilization systems and consumables
Radiation sterilization technologies
Sterilization verification system
The testing market includes the use of diagnostic equipment and consumables to detect infections and determine the best treatment plan. These include:
Immunoassays
Microbial identification and sensitivity tests
Molecular and DNA tests
To prevent infection, all possible measures are taken to create and maintain a therapeutic environment for the patient and healthcare workers.
In recent years, there have been improved methods for testing infected patients. For example, testing for MRSA infections can be done via a nostril swab, now an effective option in detecting bacteria. Admission screening has been effective in some areas and has reduced the spread of MRSA infections in hospitals in the United States and some European countries.
Table of Contents
CHAPTER ONE: EXECUTIVE SUMMARY -PREVENTION IS PROVING MORE COST-EFFECTIVE THAN TESTING AND TREATING HAIS
OVERVIEW
HOSPITAL SPENDING PRIORITIES
Figure 1-1 Hospital Budgets for Sanitation and Infection Control Small in Comparison to other Departments/Areas
COST OF HAIS
Figure 1-2: HAI Costs per Patient Stay
THE BASICS – ABOUT NOSOCOMIAL INFECTIONS (HAIS)
Table 1-1: Frequency of the Most Common Nosocomial Infections
MARKET SCOPE
RESEARCH METHODOLOGY
TESTING MARKET, INCLUDING THE IMPACT OF PREVENTION
Figure 1-3: HAI Testing Market Compared to HAI Prevention Market, 2010 -2021
CONCLUSIONS
CHAPTER TWO: INTRODUCTION AND INDUSTRY TRENDS
WHAT INFECTIONS ARE CONSIDERED HAIS?
DESCRIPTION OF INFECTIONS
Acinetobacter Baumannii
Clostridium Difficile
Gastroenteritis
Hospital-Acquired Pneumonia (HAP)
Pseudomonas Aeruginosa
Staphylococcus Aureus/Methicillin-Resistant Staphylococcus Aureus
Stenotrophomonas Maltophilia
Tuberculosis
Urinary Tract Infections
Vancomycin-Resistant Enterococcus
Ventilator-Associated Pneumonia (VAP)
Patient Risk Factors
General Populations at Risk for Infection
Table 2-1: Global Population at Risk for Serious Bacterial Infections, Secondary to Chronic Diseases by Selected Geographical Region
WORLD DEMOGRAPHICS
Figure 2-1: The Global Population, 2005-2050 (in millions)
Table 2-2: Global Population Trends Age 65+, 2000-2050
Assessing the Problem: Nosocomial Infection Statistics
Figure 2-2: U.S. Hospital Admissions and Percent of Healthcare-associated Infections (HAIs)
Figure 2-3: European Union Hospital Admissions and Percent of Healthcare-associated Infections (HAIs) .. 27
Hospital Length of Stay
U.S. GOVERNMENT’S NATIONAL PLAN TO PREVENT HEALTHCARE ASSOCIATED INFECTIONS (HAIS)
STEERING COMMITTEE
EPIDEMIOLOGY AND LABORATORY CAPACITY FOR INFECTIOUS DISEASES
AFFORDABLE CARE ACT (ACA) FUNDING
EMERGING INFECTIONS PROGRAM
Table 2-3: U.S. States ACA HAI Prevention Infrastructure Funding Awards, 2013-2016
THE DEPARTMENT OF HEALTH AND HUMAN SERVICES: 2017 BUDGET HIGHLIGHTS
Table 2-4: U.S. Department of Health & Human Services Fiscal Budget, 2015-2017 ($millions)
NATIONAL HEALTHCARE SAFETY NETWORK
Table 2-5: U.S. Healthcare-associated Infection Standardized Infection Ratio (SIR), 2010-2014
Figure 2-4: U.S. Healthcare-associated Infection Standardized Infection Ratio (SIR) 2012 through 2014: MRSA, CLABSI, and CAUTI Infections Down; SSI and C. Diff Infections Up
HEALTHCARE INFECTION SURVEILLANCE PROCESS
PHARMACEUTICAL MANUFACTURER AND MARKETER TRENDS
Trends in Partnerships and Alliances
Developers Trends
CHAPTER THREE: INFECTION PREVENTION
OVERVIEW OF PREVENTION TACTICS
MARKET OVERVIEW
Table 3-2: The Global Market for Hospital Infection Prevention Equipment and Consumables (Sterilization/Disinfection), 2010-2021
Healthcare Infection Prevention Market by Geographical Region
Table 3-3: The Global Market for Hospital Infection Prevention (Sterilization/Disinfection) Estimated Products Sales by Primary Geographic Region, 2010-2021
Methods of Transmission -Airborne
Methods of Transmission – Contact
Methods of Transmission -Droplet
Methods of Transmission -Vehicle
HIGH-RISK FACILITIES OR DEPARTMENTS
Acute Care Hospitals
Intensive Care Units
Emergency Departments
Burn Units
Long-term Care Facilities
Outpatient Settings
Oncology Centers
Dialysis Centers
Technology Overview
Table 3-4: Market Value for Infection Prevention Equipment and Related Consumables by Product Type, 2016
Wide Area Disinfection Methods
Software for Infection Detection and Control
Antiseptic-Coated Catheters
UV-C Reflective Coatings
Specialized Disinfection/Sterilization Systems
Sterilization vs. Disinfection
Sterilization
Disinfection
EQUIPMENT AND SOLUTIONS
Table 3-5: Market Value for Infection Prevention Equipment and Related Consumables by Technology, 2016
HEAT/STEAM STERILIZATION
Product Examples -Advanced Sterilization Products
Product Examples – Belimed
Product Examples – Getinge
Product Examples – Steris Corporation
CHEMICAL AND GAS STERILIZATION
Disinfecting Agents and Medical Device Components
Sterilants
Table 3-6: Summary of Advantages and Disadvantages of Chemical Agents Used as Chemical Sterilants or as High-Level Disinfectants
Table 3-7: Comparison of the Characteristics of Selected Chemicals Used as High-Level Disinfectants or Chemical Sterilants
Product Examples – Advanced Sterilization Products
Product Examples – Bioquell
Product Examples – Getinge
Product Examples – Steris Corporation
Mid-Level Disinfectants
Table 3-8: Comparison of the Characteristics of Selected Hospital Disinfectants for General Disinfection of Environmental Surfaces
RADIATION STERILIZATION
Product Examples -Steriliz LLC
Product Examples – Steris Corporation
Product Examples – UltraViolet Devices, Inc.
Product Examples – Xenex Healthcare Services
Product Examples – Sterilization and Disinfection Verification and Monitoring Systems
Table 3-9: Developments, Healthcare Infection Prevention
COMPETITIVE ANALYSIS
Table 3-10: The Global Market for Hospital Infection Prevention (Sterilization/Disinfection), Leading Suppliers’ Shares, Estimates for 2016
CHAPTER FOUR: INFECTION TESTING
OVERVIEW
TOTAL MARKET SIZE AND FORECAST
Table 4-1: The Global Market for Hospital Infection Testing/Diagnostics, 2010-2021
Healthcare Infection Testing Market by Geographical Region
Table 4-2: The Global Market for Hospital Infection Testing/Diagnostics, Estimated Products Sales by Primary Geographic Region, 2010-2021
TESTING FOR NOSOCOMIAL INFECTIONS
Drug-Resistance/Susceptibility Testing
Genotypic Methods
DNA Sequencing
Solid-phase Hybridization Techniques
Microarrays
Real-time Polymerase Chain Reaction Techniques
Phenotypic Methods
Phage-based Assays
Colorimetric Methods
The Nitrate Reductase Assay
Chromogenic Testing
Table 4-3: Market Value for Nosocomial Infection Diagnostics by Class, 2016
SPECIFIC SERIOUS HEALTHCARE INFECTION TESTING
Table 4-4: Tested Samples, Pathogens Isolated by Infection Type
Acinetobacter Baumannii
Carbapenem-resistant Enterobacteriaceae
Clostridium Difficile
Product Examples
Hospital-Acquired Pneumonia
Pseudomonas Aeruginosa
Staphylococcus Aureus
Methicillin-resistant Staphylococcus Aureus (MRSA)
Vancomycin-Intermediate/Resistant Staphylococcus Aureus (VISA/VRSA)
Products -AdvanDx, Inc. (OpGen)
Products – Becton, Dickinson
Products – Cepheid
Products – Luminex Corporation
Products -Quest
Products – Roche
Products – Tuberculosis
Product Examples and Developments
Products – Urinary Tract Infections
Vancomycin-resistant Enterococcus
Ventilator-Associated Pneumonia
Table 4-5: Significant Approvals for Detecting Serious Healthcare Infections
HAI PREVENTION AND TESTING COMPETITIVE ANALYSIS
3M
Abbott Laboratories
Advanced Sterilization Products
Alere
Becton, Dickinson and Company
Belimed
bioMérieux S.A.
Cantel Medical Corp.
Danaher
Getinge Group
Roche
Steris plc
TSO3, Inc.
